Fig. 2: Effect of chronic oxytocin administration on salivary oxytocin levels and OXTR DNAm levels.
From: Chronic oxytocin administration stimulates the oxytocinergic system in children with autism
Salivary oxytocin levels are visualised for each nasal spray group (oxytocin and placebo) at each assessment session: baseline (T0), ≥24 hours post-nasal spray (T1) and four weeks post-nasal spray (T2). Panel A shows the morning oxytocin levels (AM sample; T0: noxytocin = 39, nplacebo = 39; T1: noxytocin = 39, nplacebo = 36; T2: noxytocin = 38, nplacebo = 34) and panel B the afternoon oxytocin levels (PM sample; T0: noxytocin = 38, nplacebo = 39; T1: noxytocin = 39, nplacebo = 39; T2: noxytocin = 38, nplacebo = 37). Panel C visualises the salivary OXTR DNAm levels at CpG −924 for each nasal spray group (oxytocin and placebo) at each assessment session (T0: noxytocin = 38, nplacebo = 39; T1: noxytocin = 37, nplacebo = 38; T2: noxytocin = 38, nplacebo = 37). Data are presented as mean values, vertical bars denote standard errors. Panel D visualises the association of salivary oxytocin levels (averaged over the morning and afternoon samples) with the salivary OXTR DNAm levels in CpG −924 in the oxytocin group at T1. Source data are provided as a Supplementary Data Source file.
